|
Real-time Estimate
Cboe BZX
17:36:55 18/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 9.220 USD | +1.65% |
|
-11.45% | -41.77% |
| 11-16 | Monte Rosa Therapeutics, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 12:00 PM | |
| 11-09 | Monte Rosa Therapeutics Presents Preclinical Data On MRT-8102 In Gout | CI |
| Market Cap | 775M 707M 654M 590M 1.11B 72.42B 1.15B 7.89B 3.12B 39.09B 2.91B 2.85B 123B | P/E 2026 * |
-8.58x | P/E 2027 * | -4.95x |
|---|---|---|---|---|---|
| Enterprise Value | 236M 215M 199M 180M 338M 22.06B 352M 2.4B 950M 11.91B 885M 867M 37.59B | EV / Sales 2026 * |
2.31x | EV / Sales 2027 * | 4.25x |
| Free-Float |
99.25% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GLUE | Delayed | |
| GLUE | Real-time |
Last Transcript: Monte Rosa Therapeutics, Inc.
| 1 day | +1.87% | ||
| 1 week | -11.45% | ||
| Current month | -15.15% | ||
| 1 month | -14.35% | ||
| 3 months | -39.25% | ||
| 6 months | -49.31% | ||
| Current year | -41.77% |
| 1 week | 8.83 | 10.28 | |
| 1 month | 8.83 | 11.74 | |
| Current year | 8.83 | 25.77 | |
| 1 year | 8.83 | 25.77 | |
| 3 years | 2.91 | 25.77 | |
| 5 years | 2.44 | 25.77 | |
| 10 years | 2.44 | 45.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 55 | 31/12/2019 |
Magnus Walter
CTO | Chief Tech/Sci/R&D Officer | - | 16/03/2026 |
| Chief Operating Officer | 54 | 28/02/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Markus Warmuth
BRD | Director/Board Member | 55 | 31/12/2019 |
Ali Behbahani
BRD | Director/Board Member | 49 | 31/03/2020 |
| Director/Board Member | 57 | 31/05/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 05/10/26 | Sell | Controller/Auditor | -13 | 0.0000% | ||
| 16/07/26 | Sell | Chief Executive Officer | -9,500 | 0.0112% | ||
| 15/07/26 | Exercice | Chief Operating Officer | 13,053 | 0.0155% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.65% | -11.45% | -33.74% | +180.92% | 775M | ||
| -1.34% | -4.12% | +53.70% | +68.83% | 66.37B | ||
| +0.59% | -1.83% | +8.98% | +90.68% | 58.86B | ||
| +0.54% | +0.45% | +25.96% | +86.62% | 55.22B | ||
| -1.95% | -3.55% | +11.31% | +115.60% | 47.21B | ||
| +0.41% | -6.20% | +18.52% | +25.44% | 42.45B | ||
| -2.58% | +2.22% | +14.73% | +41.28% | 36.44B | ||
| -1.14% | -11.07% | +127.68% | +639.51% | 35.19B | ||
| -0.17% | -1.83% | +82.46% | +57.48% | 32.66B | ||
| -0.84% | +0.16% | -40.01% | +391.25% | 26.73B | ||
| Average | -0.43% | -4.02% | +26.96% | +169.76% | 40B | |
| Weighted average by Cap. | -0.63% | -2.94% | +33.52% | +143.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 102M 93.27M 86.23M 77.82M 147M 9.56B 152M 1.04B 412M 5.16B 384M 376M 16.29B | 62.16M 56.69M 52.42M 47.31M 89.09M 5.81B 92.61M 633M 250M 3.14B 233M 228M 9.9B |
| Net income | -107M -97.4M -90.06M -81.27M -153M -9.98B -159M -1.09B -430M -5.39B -401M -392M -17.01B | -194M -177M -164M -148M -278M -18.12B -289M -1.97B -781M -9.78B -728M -712M -30.89B |
| Net Debt | -539M -492M -455M -410M -772M -50.37B -803M -5.49B -2.17B -27.19B -2.02B -1.98B -85.85B | -511M -466M -431M -389M -732M -47.71B -761M -5.2B -2.06B -25.75B -1.92B -1.88B -81.32B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/11/26 | US$9.200 | +1.43% | 368,916 |
| 17/11/26 | US$9.070 | -0.98% | 1,176,563 |
| 16/11/26 | US$9.160 | -2.24% | 881,028 |
| 13/11/26 | US$9.370 | +0.64% | 1,119,299 |
| 12/11/26 | US$9.310 | -9.70% | 1,245,710 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- GLUE Stock
Select your edition
All financial news and data tailored to specific country editions
















